The results of the ABPI survey on partnership working between the pharmaceutical industry and the university sector have been published today.
The publication Enriching research, training scientists shows that industry support for academia remains strong, especially in post-graduate training, but the results also reflect the changing shape of the industry, as externalisation leads to more collaborative research and development.
Sarah Jones, ABPI Education and Skills Manager, comments:
“With ever-increasing cost pressures and the greatest ever patent cliff this is a difficult time for our industry, and these programmes represent major investments by pharmaceutical companies and are often worth millions of pounds. This continued investment shows just how important it is that we continue to support and encourage students like Jess; they are not just the next generation of analysts and researchers, they are also the people who will help us to find the treatments and cures of the future.”
Jess Sheasby, Industrial Placement Business Analyst, GSK, describes the benefits of her placement:
“This has been incredibly rewarding experience. Working in an Industrial Placement has helped me to understand the industry environment, and by working on a variety of projects I have built my knowledge and developed my skills, gaining invaluable experience. I’ve also built great contacts and will have strong references when I graduate and look for a full-time role. I highly recommend it to students, and would encourage pharmaceutical companies to continue and develop the Industrial Placement scheme.”
Previous case studies:
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: email@example.com
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.